60832-72-6

Basic information

• Product Name: 2,3-Dihydropyrido[2,3-d][1,3]oxazol-2-one
• Synonyms: (1,3 )oxazolo( 4,5-b) pyridin-2(3H)-one;2,3-Dihydropyrido[2;2H,3H-[1,3]oxazolo[4,5-b]pyridin-2-one;(1,3) OXAZOLO (4,5-B) PYRIDINE-2(3H)-ONE;2,3-Dihydropyrido[2,3-d]oxazol-2-one;3H-OXAZOLO[4,5-B]PYRIDIN-2-ONE;2,3-DIHYDROPYRIDO[2,3-D][1,3]OXAZOL-2-ONE;[1,3]Oxazolo[4,5-b]pyridin-2-ol
• CAS NO: 60832-72-6
• Molecular Formula: C6H4N2O2
• Molecular Weight: 136.11
• Product Categories: Aromatics;Heterocycles
• Mol File: 60832-72-6.mol
• Article Data: 34

Chemical Properties

• Melting Point: 214 °C
• Boiling Point: 253.8±23.0 °C(Predicted)
• Appearance: /Solid
• Density: 1.428 g/cm³
• Refractive Index: 1.595
• Storage Temp.: Refrigerator
• Solubility: DMSO, Methanol
• PKA: 2.76±0.20(Predicted)
• CAS DataBase Reference: 2,3-Dihydropyrido[2,3-d][1,3]oxazol-2-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2,3-Dihydropyrido[2,3-d][1,3]oxazol-2-one(60832-72-6)
• EPA Substance Registry System: 2,3-Dihydropyrido[2,3-d][1,3]oxazol-2-one(60832-72-6)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 20/21/22-36/37/38-36-22
• Safety Statements: 22-26-36/37/39
• Hazardous Substances Data: 60832-72-6(Hazardous Substances Data)

Usage

Chemical Properties

Tan Solid

Uses

2,3-Dihydropyrido[2,3-d][1,3]oxazol-2-one is a benzoxazolone analogue that may be used to inhibit the nitric oxide synthases (NOS).

InChI:InChI=1/C6H4N2O2/c9-6-8-5-4(10-6)2-1-3-7-5/h1-3H,(H,7,8,9)

Upstream product

• 80-48-8 methyl p-toluene sulfonate 
• 933-90-4 3-hydroxypyridine-2-carboxamide 
• 106840-72-6 2-(ethoxycarbonylamino)-3-hydroxypyridine 
• 101-84-8 diphenylether 
• 16867-03-1 2-amino-3-hydroxypyridine 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 530-62-1 1,1'-carbonyldiimidazole 
• 64269-79-0 Carbonyldiimidazole 
• 75-15-0 carbon disulfide 
• 15128-82-2 3-hydroxy-2-nitropyridine 
• 201230-82-2 carbon monoxide 
• 57-13-6 urea 
• 32276-00-9 S,S-bis(1-phenyl-1H-tetrazol-5-yl) dithiocarbonate 
• 74124-79-1 di(succinimido) carbonate 

Downstream Products

• 1456505-16-0 3-(trans-4-((4S)-5,5-dimethyl-2-oxo-4-phenyl-1,3-oxazolidin-3-yl)cyclohexyl)[1,3]oxazolo[4,5-b]pyridin-2(3H)-one 
• 1207175-73-2 5-bromo-3-hydroxy-2-tert-butyloxycarbonylaminopyridine 
• 877399-52-5 crizotinib 
• 40966-87-8 2-amino-5-chloro-3-hydroxypyridine 
• 908248-27-1 2-amino-5-nitropyridin-3-ol 
• 1452561-13-5 benzyl (trans-3-(2-oxooxazolo[4,5-b]pyridin-3(2H)-yl)cyclobutyl)carbamate 
• 1353677-04-9 3-(4-nitrophenyl)[1,3]oxazolo[4,5-b]pyridin-2(3H)-one 
• 35570-68-4 6-chlorooxazole[4,5-b]pyridine-2(3H)-one 

Relevant articles and documents

Novel antiinflammatory analgesics: 3-(2-/4-Pyridylethyl)- benzoxazolinone and oxazolo[4,5-b]pyridin-2-one derivatives

Twenty-two new 3-[2-(2- and/or 4-pyridyl)ethyl]benzoxazolinone and oxazolo[4,5-b]pyridin-2-one derivatives have been synthesized by reacting 2- and/or 4-vinylpyridine and appropriate benzoxazolinones and oxazolo[4,5- b]pyridine-2-one. Their chemical structures have been proven by IR, 1H-NMR, 13C-NMR, mass spectroscopy, and elemental analysis. The analgesic activities of these compounds were investigated by a modified Koster's Test. Test results revealed that, at 100 mg/kg dose level, most of the compounds showed significant analgesic activities when compared to aspirin. Therefore the compounds were screened for their antiinflammatory activities using the carrageenan hind paw edema test. Compounds 1, 7, 10, 11, 12, 13, 15, 18, 20, 21 were found more active than indomethacine. In gastric ulceration studies gastrointestinal bleeding was not observed at 100 mg/kg dose level in compounds 1 and 2.

Synthesis of Novel Oxazolo[4,5-b]pyridine-2-one based 1,2,3-triazoles as Glycogen Synthase Kinase-3β Inhibitors with Anti-inflammatory Potential

A novel series of oxazolo[4,5-b]pyridine-2-one based 1,2,3-triazoles has been synthesized by click chemistry approach and evaluated for in vitro GSK-3β inhibitory activity. Compound 4g showed maximum inhibition with IC50 value of 0.19 μm. Keeping in view the effect of GSK-3β inhibition on inflammation, compounds 4g, 4d, 4f, 4i, 4n and 4q exhibiting significant GSK-3β inhibition were examined for in vivo anti-inflammatory activity in rat paw edema model. The compounds 4g, 4d, 4f and 4i showed pronounced in vivo anti-inflammatory activity (76.36, 74.54, 72.72 and 70.90%, respectively, after 5h post-carrageenan administration) and were further found to inhibit the pro-inflammatory mediators, viz. NO, TNF-α, IL-1β, and IL-6 substantially in comparison with indomethacin, an anti-inflammatory drug as well as SB216763, a GSK-3β inhibitor, reported to exert a similar effect. Histopathology studies confirmed the tolerance of gastric mucosa to these compounds.

HETEROARYL COMPOUNDS AS KINASE INHIBITOR

Provided herein are heteroaryl compounds of formula (I) having activity on a receptor protein tyrosine kinase, wherein R 1, R 2, R 3, A, Q, Z, X and W are set forth in the description, as well as solvates, hydrates, tautomers or pharmaceutically acceptable salts thereof.

Preparation method of azamethiphos intermediate 3H-oxazolo[4,5-b]pyridin-2-one

A preparation method of an azamethiphos intermediate 3H-oxazolo[4,5-b]pyridin-2-one includes the technological steps that 1, 2-amino-3-pyridinol is dissolved in a solvent; 2, alkali is added; 3, a triphosgene organic solution is dripped at -5-30 DEG C; 4, a reaction is carried out for 2-20 h at 40-90 DEG C; 5, solid-liquid separation is carried out after the temperature is cooled to 0-20 DEG C; 6, drying is carried out, and the azamethiphos intermediate 6-chloro-3H-oxazolo[4,5-b]pyridin-2-one is obtained. Compared with the prior art, according to the method, reaction steps are short, operation is easy, and reaction conditions are mild; besides, as triphosgene with low toxicity is used for replacing high-toxicity phosgene, the reaction yield reaches up to 85%, the organic solvent can be recycled and reused, and the method is suitable for industrial production.